MedTrace Logo

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

NCT00772395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2014-09-19

No results posted yet for this study

Summary

Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?

Conditions

  • Bone Loss

Interventions

DRUG

Risedronate

35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)

DRUG

Placebo

Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Danderyd Hospital

    lead OTHER

Principal Investigators

  • Olof G Sköldenberg, MD · Department of clinical sciences at Danderyd hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00772395 on ClinicalTrials.gov